Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 510 participants.

Also called NCT03568890

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 510 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03568890
Other papers using this trial's data
  • Short-Term Anticoagulation Versus Dual Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure: The ANDES Randomized Clinical Trial Circulation, 2025-12-23 DOI, PubMed 41139402

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT03568890. Randomized; no masking; primary purpose prevention. Start 2018-09-01 (actual); primary completion 2025-08-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure
Acronym
ANDES
Condition
Left Atrial Appendage Closure
Condition
Thrombosis
Condition
Stroke
Condition
Bleeding
Intervention (Drug)
Rivaroxaban, dabigatran, apixaban, or edoxaban
Intervention (Drug)
Clopidogrel -75 mg/day
Intervention (Drug)
Low dose aspirin -80 to 125 mg/day-
Lead sponsor
Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec (class: other)

Record details

Record id
cardio:ct-nct03568890
Content hash
0f598330ffc91c33f3c6705087853411bcdcb57422df722677e5ab2115eee50f